THANKS FOR REACHING OUT!
We’ll be in touch to follow up.
Additional Two Labs Insights
Our experts Anita Dopkosky, RPh, and Courtney Johnson discuss how to identify priorities and then build a launch plan that supports them; how to identify critical path milestones; and how to weigh all options when creating a distribution channel strategy.
Thousands of rare diseases affect hundreds of millions of people globally, and hope for treatment is on the rise in the form of cell and gene therapies. While only 9 cell and gene therapies are currently FDA-approved in the U.S., that number is soon expected to grow exponentially. With such drastic change on the horizon, the industry needs to be prepared.